AIXC — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-05-11

• ● The projected financial information, anticipated growth rate, and market opportunities of the Company;

• ● The ability to maintain the listing of our Common Stock on Nasdaq;

• ● Our success in retaining or recruiting, or changes required in, officers, key employees, or directors;

• ● Our future financial performance and capital requirements;

• ● The trends in, expected growth in and market size of the blockchain and Fintech industries in the markets we have business and globally;

Text removed vs the prior filing · source: 10-Q · 2025-11-14

• ● our ability to procure sufficient working capital to continue and complete the development, testing and launch of our prospective drug products;

• ● our ability to progress our drug candidates through preclinical and clinical development;

• ● our ability to obtain the requisite regulatory approvals for our clinical trials and to begin and complete such trials according to any projected timeline;

• ● our ability to complete enrollment in our clinical trials as contemplated by any projected timeline;

• ● the likelihood that future clinical trial data will be favorable or that such trials will confirm any improvements over other products or lack negative impacts;

Text added vs the prior filing · source: 10-Q · 2026-05-11

• On June 27, 2025, our Co-Chief Executive Officer, Jiawei (Jerry) Wang, received a “Wells Notice” from the staff of the Securities and Exchange Commission (the “SEC” ). Subsequently, on June 30, 2025, Mr. YT Jia, who has been appointed as our Chief Advisor, also received a Wells Notice from the SEC.

• The notices state that the SEC staff has made a preliminary determination to recommend filing an enforcement action against Mr. Wang and Mr. Jia in their individual capacities. The alleged violations involve various anti-fraud provisions of the federal securities laws pertaining to purported false o…

• The staff’s recommendation for an enforcement action may seek an injunction or cease-and-desist order, civil monetary penalties, disgorgement, or other equitable relief. The SEC may also seek a formal bar preventing Mr. Wang and Mr. Jia from serving as an officer or director of a public company.

• A Wells Notice is neither a formal charge of wrongdoing nor a final determination that the recipient has violated any law. It is a preliminary determination by the SEC staff to recommend to the Commissioners of the SEC that a civil enforcement action or administrative proceeding be brought. If the S…

• In September 2025, both Mr. Wang and Mr. Jia submitted formal responses to the SEC outlining why they believed an enforcement action is unwarranted. On March 18, 2026, the SEC’s Division of Enforcement issued letters directly to Faraday Future Intelligent Electric, Inc., Mr. Wang and Mr. Jia stating…

Text removed vs the prior filing · source: 10-Q · 2025-11-14

• As previously disclosed in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, the Company is a party to certain legal proceedings. There have been no material developments with respect to these matters during the quarter ended September 30, 2025. The description of thes…

• From time to time, we could become involved in disputes and various litigation matters that arise in the normal course of business. These may include disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters. The Company is not aware of any pendin…